Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease
May 18 2020 - 4:05PM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, announced today that
it will host a virtual Key Opinion Leader (KOL) event on
cisplatin-induced chronic kidney disease on Friday, May 22, 2020,
from 10 a.m. to 11 a.m. EDT.
The event will feature a panel discussion regarding
the clinical challenges of nephrotoxicity of platinum-based
chemotherapy (cisplatin) in the treatment of patients with head and
neck cancer, and a summary of the preliminary findings from a
retrospective analysis of Phase 2b trial data in patients with head
and neck cancer and the potential role of avasopasem manganese
(GC4419) in this patient population.
The live audio webcast of the event will be accessible from the
Investors page of Galera’s website, investors.galeratx.com.
Individuals can participate in an interactive Q&A by submitting
questions via the webcast platform.
An archived version of the webcast will be available in the News
& Events section of the Investors page of Galera’s website for
60 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing a pipeline of
novel, proprietary therapeutics that have the potential to
transform radiotherapy in cancer. Galera’s lead product candidate
is avasopasem manganese (GC4419), a highly selective small molecule
superoxide dismutase (SOD) mimetic initially being developed for
the reduction of radiation-induced severe oral mucositis (SOM).
Avasopasem manganese is being studied in the Phase 3 ROMAN trial
for its ability to reduce the incidence and severity of SOM induced
by radiotherapy in patients with locally advanced head and neck
cancer, its lead indication, and in the Phase 2a trial for its
ability to reduce the incidence of esophagitis induced by
radiotherapy in patients with lung cancer. The FDA granted Fast
Track and Breakthrough Therapy designations to avasopasem manganese
for the reduction of SOM induced by radiotherapy. Galera is
developing a second product candidate, GC4711, which successfully
completed Phase 1 trials in healthy volunteers. Galera is
headquartered in Malvern, PA. For more information, please visit
www.galeratx.com.
Investor Contacts:Christopher DegnanGalera
Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
Chiara RussoSolebury
Trout617-221-9197crusso@soleburytrout.com
Media Contact:Heather Anderson6
Degrees919-827-5539handerson@6degreespr.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Apr 2024 to May 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From May 2023 to May 2024